Clinical Trials Logo

ALL, Adult clinical trials

View clinical trials related to ALL, Adult.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06250959 Recruiting - ALL, Adult Clinical Trials

RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.

BEAT-ALL-2024
Start date: February 5, 2024
Phase: Phase 2
Study type: Interventional

In this study, newly diagnosed non-elderly patients with Philadelphia chromosomal negative (PH-) B-ALL were enrolled and 1:1 randomised into Reduced-intensity chemotherapy followed by Blinatumomab cohort or hyperCVAD cohort as induction therapy. The clinical remission rate, MRD negative rate and treaty-related adverse reactions were evaluated.

NCT ID: NCT06052813 Recruiting - AML, Adult Clinical Trials

A Study of BN104 in the Treatment of Acute Leukemia

Start date: September 16, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The Phase I/II trial is to learn the safety, pharmacokinetics, and preliminary efficacy of BN104 taken once daily or twice daily in patients with acute lymphocytic leukemia or acute myeloblastic leukemia.

NCT ID: NCT05480904 Recruiting - Solid Tumor Clinical Trials

Characterizing Sleep Among Long-term Survivors of Childhood Cancer

Start date: April 17, 2023
Phase:
Study type: Observational

The patients are being asked to take part in this clinical trial because they received cancer treatment as a child at St. Jude. The study comprehensively examines sleep among three distinct diagnostic groups of survivors in the SJLIFE cohort: ALL, CNS tumors, and non-CNS solid tumors. Primary Objective The primary aim of this protocol is to estimate the prevalence of various sleep disorders among long-term survivors of childhood ALL, CNS tumors, and non- CNS solid tumors. Exploratory Objective The exploratory objective of the study is to explore associations between the prevalence of sleep disorders and clinical outcomes collected in SJLIFE.

NCT ID: NCT05473910 Recruiting - Clinical trials for Myelodysplastic Syndromes

A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation

Start date: November 1, 2022
Phase: Phase 1
Study type: Interventional

This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor.

NCT ID: NCT05026229 Recruiting - Clinical trials for Precursor Cell Lymphoblastic Leukemia-Lymphoma

A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL

Start date: September 6, 2021
Phase: N/A
Study type: Interventional

This project is a key clinical research project approved by the Clinical Research Center of the First Affiliated Hospital of Xi'an Jiaotong University. Tyrosine kinase inhibitors (TKI) combined with intensive chemotherapy has markedly improved the outcomes of philadelpha-positive lymphoblastic leukemia (Ph+ ALL). However, a considerable proportion of patients failed to complete the intended chemotherapy and some even died early. The optimal balance between the intensity of chemotherapy and safety should be explored. In this study, Ph+ ALL patients who achieve complete remission (CR) after VP regimen (vincristine and prednisone) plus dasatinib as induction are enrolled and then the participants will receive different consolidation chemotherapy. Patients in the group A will continue to use VP regimen plus dasatinib, while the group B receives hyper-CVAD/methotrexate-cytarabine regimen plus dasatinib. The measurable residual disease (MRD), CR, adverse effects (AE), overall survival (OS) and disease free survival (DFS) will be observed to determine the proper consolidation chemotherapy regimen.

NCT ID: NCT05024357 Recruiting - Clinical trials for Precursor Cell Lymphoblastic Leukemia-Lymphoma

A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL

Start date: September 6, 2021
Phase: N/A
Study type: Interventional

This project is a key clinical research project approved by the Clinical Research Center of the First Affiliated Hospital of Xi 'an Jiaotong University.Tyrosine kinase inhibitors (TKI) combined with chemotherapy and subsequent allogeneic hematopoietic stem cell transplantation (allo-HSCT) are routinely used in patients with philadelpha-positive lymphoblastic leukemia (Ph+ALL). However, TKI maintenance therapy post-HSCT remains controversial. In this study, Ph+ALL patients are enrolled and given dasatinib combined with chemotherapy followed by allo-HSCT. Then patients in the group A continuing to use dasatinib for 1 year is compared with those in the group B receiving dasatinib for 6 months after HSCT. The measurable residual disease (MRD), complete remission (CR), overall survival (OS), disease free survival (DFS), non-relapse mortality (NRM) and the incidence of graft versus host disease (GVHD) will be observed to determine the optimal duration of TKI maintenance therapy post-HSCT.

NCT ID: NCT04722848 Recruiting - ALL, Adult Clinical Trials

Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL

Start date: September 8, 2021
Phase: Phase 3
Study type: Interventional

This is a randomised, open-label, multicenter, phase III study for adult de novo Ph+ ALL patients based on the combination of Ponatinib with Blinatumomab. The control arm will be represented by a chemotherapeutic scheme combined with Imatinib for patients aged 18-65 and by Imatinib plus age-adjusted chemotherapy for elderly patients (>65 years old). Patients will be randomized 2:1 to receive the experimental or control arm. If patients in the control arm do not achieve a CHR and/or MRD negativity, after the sixth consolidation cycle (week 20), a crossover to receive Blinatumomab is planned. Likewise, if patients in the control arm develop an ABL1 mutation at any time of treatment, they will switch to experimental arm. HLA typing will be performed immediately after diagnosis in both arms for patients aged up to 65 years. After the 2 cycles of Blinatumomab in the experimental arm and after consolidation in the control arm, patients aged 18-65 will be stratified for transplant allocation.

NCT ID: NCT04482894 Recruiting - Clinical trials for Myelodysplastic Syndromes

Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS

Start date: August 19, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to estimate the potential benefit of early and continued palliative care (PC) consultation on end of life issues.

NCT ID: NCT03884829 Recruiting - Clinical trials for Myelodysplastic Syndromes

A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

Start date: March 25, 2019
Phase: Phase 1
Study type: Interventional

A Phase I Pharmacologic Study of CYC140, a polo-like kinase 1 inhibitor, in Patients with Advanced Leukemias or Myelodysplastic Syndromes